基于微量全血基因表达特征诊断川崎病
该病例对照研究旨在识别能区分川崎病(KD)与其他发热疾病的儿童全血基因表达特征。研究在发现集(404例患儿及55名健康对照)中构建了13转录本特征,并在独立验证集(102例KD,包括72例发病7天内;130例发热对照)中验证。结果显示,该特征在验证集中区分KD与发热对照的AUC为94.6%(95%CI,91.3%-98.0%),灵敏度85.9%,特异度89.1%,且诊断准确性随临床诊断确定性增加而提高。
要点
- 13转录本全血基因表达特征可区分川崎病与其他发热疾病。
- 验证集AUC为94.6%,灵敏度85.9%,特异度89.1%。
- 诊断准确性随临床诊断确定性增加而提高。
核心结论
- 13转录本血液基因表达特征能够区分川崎病与其他发热状况。
- 诊断准确性随临床诊断确定性增加而提高。
研究设计与样本
- 病例对照研究,包括发现组(含训练集和测试集)和独立验证组。
- 发现组由404例感染性和炎症性疾病患儿(78例KD、84例其他炎症性疾病、242例细菌或病毒感染)及55名健康对照组成。
- 独立验证组由102例KD患者(其中72例处于发病7天内)和130例发热对照组成。
主要发现
- 发现测试集中,13转录本特征区分KD与其他感染和炎症性疾病的AUC为96.2%(95%CI,92.5%-99.9%),灵敏度81.7%(95%CI,60.0%-94.8%),特异度92.1%(95%CI,84.0%-97.0%)。
- 验证集中,该特征区分KD与发热对照的AUC为94.6%(95%CI,91.3%-98.0%),灵敏度85.9%(95%CI,76.8%-92.6%),特异度89.1%(95%CI,83.0%-93.7%)。
- 该特征应用于临床定义的肯定、高度可能和可能KD类别时,AUC分别为98.1%(95%CI,94.5%-100%)、96.3%(95%CI,93.3%-99.4%)和70.0%(95%CI,53.4%-86.6%)。
关键数值与推荐
- 发现测试集:AUC 96.2%(95%CI,92.5%-99.9%),灵敏度81.7%(95%CI,60.0%-94.8%),特异度92.1%(95%CI,84.0%-97.0%)。
- 验证集:AUC 94.6%(95%CI,91.3%-98.0%),灵敏度85.9%(95%CI,76.8%-92.6%),特异度89.1%(95%CI,83.0%-93.7%)。
- 临床肯定KD:AUC 98.1%(95%CI,94.5%-100%);高度可能KD:AUC 96.3%(95%CI,93.3%-99.4%);可能KD:AUC 70.0%(95%CI,53.4%-86.6%)。
临床怎么用
- 整合13转录本病风险评分的检测可能有助于川崎病的早期诊断和治疗。
- 该检测可能减少对其他诊断患者的不适当治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To date, there is no diagnostic test for Kawasaki disease (KD). Diagnosis is based on clinical features shared with other febrile conditions, frequently resulting in delayed or missed treatment and an increased risk of coronary artery aneurysms. OBJECTIVE: To identify a whole-blood gene expression signature that distinguishes children with KD in the first week of illness from other febrile conditions. DESIGN, SETTING, AND PARTICIPANTS: The case-control study comprised a discovery group that included a training and test set and a validation group of children with KD or comparator febrile illness. The setting was pediatric centers in the United Kingdom, Spain, the Netherlands, and the United States. The training and test discovery group comprised 404 children with infectious and inflammatory conditions (78 KD, 84 other inflammatory diseases, and 242 bacterial or viral infections) and 55 healthy controls. The independent validation group comprised 102 patients with KD, including 72 in the first 7 days of illness, and 130 febrile controls. The study dates were March 1, 2009, to November 14, 2013, and data analysis took place from January 1, 2015, to December 31, 2017. MAIN OUTCOMES AND MEASURES: Whole-blood gene expression was evaluated using microarrays, and minimal transcript sets distinguishing KD were identified using a novel variable selection method (parallel regularized regression model search). The ability of transcript signatures (implemented as disease risk scores) to discriminate KD cases from controls was assessed by area under the curve (AUC), sensitivity, and specificity at the optimal cut point according to the Youden index. RESULTS: Among 404 patients in the discovery set, there were 78 with KD (median age, 27 months; 55.1% male) and 326 febrile controls (median age, 37 months; 56.4% male). Among 202 patients in the validation set, there were 72 with KD (median age, 34 months; 62.5% male) and 130 febrile controls (median age, 17 months; 56.9% male). A 13-transcript signature identified in the discovery training set distinguished KD from other infectious and inflammatory conditions in the discovery test set, with AUC of 96.2% (95% CI, 92.5%-99.9%), sensitivity of 81.7% (95% CI, 60.0%-94.8%), and specificity of 92.1% (95% CI, 84.0%-97.0%). In the validation set, the signature distinguished KD from febrile controls, with AUC of 94.6% (95% CI, 91.3%-98.0%), sensitivity of 85.9% (95% CI, 76.8%-92.6%), and specificity of 89.1% (95% CI, 83.0%-93.7%). The signature was applied to clinically defined categories of definite, highly probable, and possible KD, resulting in AUCs of 98.1% (95% CI, 94.5%-100%), 96.3% (95% CI, 93.3%-99.4%), and 70.0% (95% CI, 53.4%-86.6%), respectively, mirroring certainty of clinical diagnosis. CONCLUSIONS AND RELEVANCE: In this study, a 13-transcript blood gene expression signature distinguished KD from other febrile conditions. Diagnostic accuracy increased with certainty of clinical diagnosis. A test incorporating the 13-transcript disease risk score may enable earlier diagnosis and treatment of KD and reduce inappropriate treatment in those with other diagnoses.
引用
- Wright VJ, Herberg JA, Kaforou M, et al. Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature. JAMA Pediatr. 2018. PMID: 30083721. doi:10.1001/jamapediatrics.2018.2293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。